Generic placeholder image

Current Nutraceuticals

Author(s): Ritesh Kumar Tiwari*, Lalit Singh , Shashi Verma and Vijay Sharma

DOI: 10.2174/2665978601999200930143521

DownloadDownload PDF Flyer Cite As
Formulation and Evaluation of Isabgol and Liquorice-Based Nutraceuticals Floating Tablets for Management of Gastric Ulcer

Page: [56 - 61] Pages: 6

  • * (Excluding Mailing and Handling)

Abstract

Background: Floating tablets extend drug residence time, enhance bioavailability and promote the delivery of local drugs to the stomach. With this objective, floating tablets were prepared for the treatment of gastric ulcers containing aqueous extract of liquorice and Isabgol.

Methods: Tablets containing HPMC K100M (hydrophilic polymer), liquorice extract, sodium bicarbonate (gas generating agent), talc, and magnesium stearate were prepared using direct compression method. Physical parameters of formulations such as diameter, thickness, hardness, friability, weight uniformity, drug content, buoyancy time, dissolution, and the mechanism for drug release, were assessed. The formulations have been optimized based on buoyancy time and invitro drug release.

Results: The diameter of all formulations was in the range 11.310-11.833 mm; thickness was in the range 4.02-4.071 mm. The hardness ranged from 3.1 to 3.4 kg/cm. All the formulations passed the USP requirements for friability and uniformity of weight. All tablet formulations had a buoyancy period of less than 5 min and throughout the research, the tablet stayed in floating condition. All tablet formulations were accompanied in drug discharge by zero-order kinetics and Korsmeyer- Peppas model.

Conclusion: It was discovered that the optimized formulation was F7, which released 98.5 percent of the drug in 8 hr. in-vitro, while the buoyancy time was 3.5 min. For gastroretentive drug delivery systems, formulations containing Isabgol, sodium bicarbonate and HPMC K100 M in combination may be promising.

Keywords: Nutraceutical, floating tablets, isabgol, liquorice extract, gastric ulcer, floating drug delivery system.

Graphical Abstract

[1]
Upendra, N.; Ashok, K.P.; Charu Bharti, C. Gulati, N. Formulation and evaluation of nutraceutical tablet using herbal drugs by direct compression method. J. Drug Deliv. Ther., 2014, 4(2), 47-51.
[2]
Shanthi, A.; Radha, R.; Jaysree, N. Antiulcer activity of newly formulated herbal capsule. Asian J. Pharm. Clin. Res., 2011, 4(3), 86.
[3]
Waugh, A.; Grant, A. Wilson, R.; Anatomy & Physiology in Health and Illness, 11th ed; Churchill Livingstone: New York, 2013, p. 315.
[4]
Yeole, P.G. floating drug delivery system: Need and development Ind. J. Pharm. Sci., 2005, 67(3), 265-272.
[5]
Garg, R.; Gupta, G.D. Progress in controlled gastrointestinal delivery systems. Trop. J. Pharm. Res., 2008, 7, 1055-1066.
[http://dx.doi.org/10.4314/tjpr.v7i3.14691]
[6]
Singh, B.N.; Kim, K.H. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J. Control. Release, 2000, 63(3), 235-259.
[http://dx.doi.org/10.1016/S0168-3659(99)00204-7 PMID: 10601721]
[7]
Rubinstein, A.; Friend, D.R. Specific delivery to the gastrointestinal tract.Domb, A. J. Chichester; Pharmacotherapy, P.S-S., Ed.; Wiley, 1994, pp. 283-285.
[8]
Streubel, A.; Siepmann, J.; Bodmeier, R. Drug delivery to the upper small intestine window using gastroretentive technologies. Curr. Opin. Pharmacol., 2006, 6(5), 501-508.
[http://dx.doi.org/10.1016/j.coph.2006.04.007 PMID: 16890020]
[9]
Deshpande, A.A.; Shah, N.H.; Rhodes, C.T.; Malick, W. Development of a novel controlled-release system for gastric retention. Pharm. Res., 1997, 14(6), 815-819.
[http://dx.doi.org/10.1023/A:1012171010492 PMID: 9210203]
[10]
Gohel, M.C.; Patel, M.M.; Amin, A.F. Development of modified release diltiazem HCl tablets using composite index to identify optimal formulation. Drug Dev. Ind. Pharm., 2003, 29(5), 565-574.
[http://dx.doi.org/10.1081/DDC-120018645 PMID: 12779286]
[11]
Bennett, A.; Melhuish, P.B.; Stamford, I.F. Carbenoxolone and deglycyrrhized liquorice have little or no effect on prostanoid synthesis by rat gastric mucosa ex vivo. Br. J. Pharmacol., 1985, 86(3), 693-695.
[http://dx.doi.org/10.1111/j.1476-5381.1985.tb08947.x PMID: 3840708]
[12]
Yano, S.; Harada, M.; Watanabe, K.; Nakamaru, K.; Hatakeyama, Y.; Shibata, S.; Takahashi, K.; Mori, T.; Hirabayashi, K.; Takeda, M. Antiulcer activities of glycyrrhetinic acid derivatives in experimental gastric lesion models. Chem. Pharm. Bull. (Tokyo), 1989, 37(9), 2500-2504.
[http://dx.doi.org/10.1248/cpb.37.2500 PMID: 2605700]
[13]
Aly, A.M.; Al-Alousi, L.; Salem, H.A. Licorice: A possible anti-inflammatory and anti-ulcer drug. AAPS PharmSciTech, 2005, 6(1), E74-E82.
[http://dx.doi.org/10.1208/pt060113 PMID: 16353966]
[14]
Masoomeh, M.J.; Kiarash, G. In vitro susceptibility of Helicobacter pylori to licorice extract. Iran. J. Pharm. Res., 2007, 6, 69-72.
[15]
Tiwari, R.K.; Singh, L.; Sharma, V.; Singh, P. Formulation development of fast dissolving tablet of clove - The best nutraceutical analgesic tablet. Asia. F. Sci., 2018, 1(3), 1-7.
[16]
Tiwari, R.K.; Singh, L.; Sharma, V. Performance optimization of sustained release arginine alginate microbeads with a natural polysaccharide. J. Pharma. Res. Int., 2017, 17(5), 1-11.
[http://dx.doi.org/10.9734/JPRI/2017/34305]
[17]
Singh, L.; Nanda, A.; Sharma, S.; Sharma, V. Design optimization and evaluation of gastric floating matrix tablet of glipizide. Trop. J. Pharm. Res., 2013, 12(6), 869-876.
[http://dx.doi.org/10.4314/tjpr.v12i6.2]
[18]
Sharma, V.; Singh, L. Formulation variable study and optimization of taste masked mouth dissolving tablets using design of experiment. D. Dev. Thera., 2015, 6(1), 20-28.
[http://dx.doi.org/10.4103/2394-2002.148887]
[19]
Singh, L.; Nanda, A.; Sharma, S.; Sharma, V. Formulation by design: understanding the formulation variables and optimisation of glipizide buoyant bioadhesive microcarriers by central composite design. Malays. J. Pharm. Sci., 2014, 12(1), 1-18.
[20]
Basak, S.C.; Rao, K.N.; Manavalan, R.; Rao, P.R. Development and in vitro evaluation of an oral floating matrix tablet formulation of ciprofloxacin. Indian J. Pharm. Sci., 2004, 66, 313-316.
[21]
Nanda, A.; Singh, L.; Sharma, S.; Sharma, V. Performance optimization of buoyant beads of anti-diabetic drug using quality by design (QbD). Lat. Am. J. Pharm., 2014, 33(1), 14-23.
[22]
Sharma, D. Formulation Development and Evaluation of Fast Disintegrating Tablets of Salbutamol Sulphate for Respiratory Disorders. ISRN Pharmaceutics,, 2013, 8Article ID 674507.
[23]
Ritger, P.L.; Peppas, N.A. A simple equation for description of solute release. II. Fickian and anomalous release from swellable devices. J. Control. Release, 1987, 5, 37-42.
[http://dx.doi.org/10.1016/0168-3659(87)90035-6]
[24]
Thadkala, K.; Perma Kumari, N.P.; Prathyusha, R.; Raju, A. Formulation development, optimization and characterization of floating beads of captopril. Int. J. Pharm. Res. Allied. Sci., 2013, 2, 32-46.